Access to clinical trials for adolescents with soft tissue sarcomas

Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols

Andrea Ferrari, Annalisa Trama, Angela De Paoli, Christophe Bergeron, Johannes H M Merks, Meriel Jenney, Daniel Orbach, Julia C Chisholm, Soledad Gallego, Heidi Glosli, Gian Luca De Salvo, Laura Botta, Gemma Gatta, Gianni Bisogno, RARECAREnet Working Group

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Adolescents with cancer are enrolled in clinical trials at far lower rates than children. This report compares the number of adolescents (15-19-year-olds) and children (0-14-year-olds) enrolled in the protocols of the European pediatric Soft tissue sarcoma Study Group (EpSSG) with the number of cases expected to occur.

METHODS: The observed-to-expected (O/E) ratio was detected in the EpSSG countries contributing most of the cases, that is, Italy, France, Spain, the Netherlands, United Kingdom, and Ireland. The observed cases included patients enrolled in any of the EpSSG protocols from October 2008 to October 2015, when all EpSSG protocols were open in these countries. The number of expected cases was calculated from the incidence rates estimated throughout the RARECAREnet database in the countries' population-based cancer registries.

RESULTS: In the countries considered, 2,118 cases aged 0-19 years were enrolled in the EpSSG trials from 2008 to 2015: 82.8% were children and 17.2% were adolescents. The O/E ratio was 0.30 among patients 15-19 years old, as opposed to 0.64 for those 0-14 years old. The O/E ratio differed for the different subtypes: in adolescents, it was 0.64 and 0.18 for rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), respectively; in children, it was 0.77 and 0.50, respectively. The O/E ratios differed across the countries considered.

CONCLUSIONS: Adolescents were less well represented than children on the EpSSG protocols, with better enrolment for RMS than for NRSTS for all age groups.

Original languageEnglish
Article numbere26348
JournalPediatric Blood and Cancer
Volume64
Issue number6
Early online dateNov 24 2016
DOIs
Publication statusPublished - Apr 23 2017

Fingerprint

Sarcoma
Clinical Trials
Pediatrics
Rhabdomyosarcoma
Ireland
Netherlands
Spain
Italy
France
Registries
Neoplasms
Age Groups
Databases
Incidence
Population

Keywords

  • Journal Article

Cite this

Access to clinical trials for adolescents with soft tissue sarcomas : Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. / Ferrari, Andrea; Trama, Annalisa; De Paoli, Angela; Bergeron, Christophe; Merks, Johannes H M; Jenney, Meriel; Orbach, Daniel; Chisholm, Julia C; Gallego, Soledad; Glosli, Heidi; De Salvo, Gian Luca; Botta, Laura; Gatta, Gemma; Bisogno, Gianni; RARECAREnet Working Group.

In: Pediatric Blood and Cancer, Vol. 64, No. 6, e26348, 23.04.2017.

Research output: Contribution to journalArticle

Ferrari, A, Trama, A, De Paoli, A, Bergeron, C, Merks, JHM, Jenney, M, Orbach, D, Chisholm, JC, Gallego, S, Glosli, H, De Salvo, GL, Botta, L, Gatta, G, Bisogno, G & RARECAREnet Working Group 2017, 'Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols', Pediatric Blood and Cancer, vol. 64, no. 6, e26348. https://doi.org/10.1002/pbc.26348
Ferrari, Andrea ; Trama, Annalisa ; De Paoli, Angela ; Bergeron, Christophe ; Merks, Johannes H M ; Jenney, Meriel ; Orbach, Daniel ; Chisholm, Julia C ; Gallego, Soledad ; Glosli, Heidi ; De Salvo, Gian Luca ; Botta, Laura ; Gatta, Gemma ; Bisogno, Gianni ; RARECAREnet Working Group. / Access to clinical trials for adolescents with soft tissue sarcomas : Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. In: Pediatric Blood and Cancer. 2017 ; Vol. 64, No. 6.
@article{c530cdd6358f40afa53d3ea2b9a8de26,
title = "Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols",
abstract = "BACKGROUND: Adolescents with cancer are enrolled in clinical trials at far lower rates than children. This report compares the number of adolescents (15-19-year-olds) and children (0-14-year-olds) enrolled in the protocols of the European pediatric Soft tissue sarcoma Study Group (EpSSG) with the number of cases expected to occur.METHODS: The observed-to-expected (O/E) ratio was detected in the EpSSG countries contributing most of the cases, that is, Italy, France, Spain, the Netherlands, United Kingdom, and Ireland. The observed cases included patients enrolled in any of the EpSSG protocols from October 2008 to October 2015, when all EpSSG protocols were open in these countries. The number of expected cases was calculated from the incidence rates estimated throughout the RARECAREnet database in the countries' population-based cancer registries.RESULTS: In the countries considered, 2,118 cases aged 0-19 years were enrolled in the EpSSG trials from 2008 to 2015: 82.8{\%} were children and 17.2{\%} were adolescents. The O/E ratio was 0.30 among patients 15-19 years old, as opposed to 0.64 for those 0-14 years old. The O/E ratio differed for the different subtypes: in adolescents, it was 0.64 and 0.18 for rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), respectively; in children, it was 0.77 and 0.50, respectively. The O/E ratios differed across the countries considered.CONCLUSIONS: Adolescents were less well represented than children on the EpSSG protocols, with better enrolment for RMS than for NRSTS for all age groups.",
keywords = "Journal Article",
author = "Andrea Ferrari and Annalisa Trama and {De Paoli}, Angela and Christophe Bergeron and Merks, {Johannes H M} and Meriel Jenney and Daniel Orbach and Chisholm, {Julia C} and Soledad Gallego and Heidi Glosli and {De Salvo}, {Gian Luca} and Laura Botta and Gemma Gatta and Gianni Bisogno and {RARECAREnet Working Group}",
note = "{\circledC} 2016 Wiley Periodicals, Inc.",
year = "2017",
month = "4",
day = "23",
doi = "10.1002/pbc.26348",
language = "English",
volume = "64",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Access to clinical trials for adolescents with soft tissue sarcomas

T2 - Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols

AU - Ferrari, Andrea

AU - Trama, Annalisa

AU - De Paoli, Angela

AU - Bergeron, Christophe

AU - Merks, Johannes H M

AU - Jenney, Meriel

AU - Orbach, Daniel

AU - Chisholm, Julia C

AU - Gallego, Soledad

AU - Glosli, Heidi

AU - De Salvo, Gian Luca

AU - Botta, Laura

AU - Gatta, Gemma

AU - Bisogno, Gianni

AU - RARECAREnet Working Group

N1 - © 2016 Wiley Periodicals, Inc.

PY - 2017/4/23

Y1 - 2017/4/23

N2 - BACKGROUND: Adolescents with cancer are enrolled in clinical trials at far lower rates than children. This report compares the number of adolescents (15-19-year-olds) and children (0-14-year-olds) enrolled in the protocols of the European pediatric Soft tissue sarcoma Study Group (EpSSG) with the number of cases expected to occur.METHODS: The observed-to-expected (O/E) ratio was detected in the EpSSG countries contributing most of the cases, that is, Italy, France, Spain, the Netherlands, United Kingdom, and Ireland. The observed cases included patients enrolled in any of the EpSSG protocols from October 2008 to October 2015, when all EpSSG protocols were open in these countries. The number of expected cases was calculated from the incidence rates estimated throughout the RARECAREnet database in the countries' population-based cancer registries.RESULTS: In the countries considered, 2,118 cases aged 0-19 years were enrolled in the EpSSG trials from 2008 to 2015: 82.8% were children and 17.2% were adolescents. The O/E ratio was 0.30 among patients 15-19 years old, as opposed to 0.64 for those 0-14 years old. The O/E ratio differed for the different subtypes: in adolescents, it was 0.64 and 0.18 for rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), respectively; in children, it was 0.77 and 0.50, respectively. The O/E ratios differed across the countries considered.CONCLUSIONS: Adolescents were less well represented than children on the EpSSG protocols, with better enrolment for RMS than for NRSTS for all age groups.

AB - BACKGROUND: Adolescents with cancer are enrolled in clinical trials at far lower rates than children. This report compares the number of adolescents (15-19-year-olds) and children (0-14-year-olds) enrolled in the protocols of the European pediatric Soft tissue sarcoma Study Group (EpSSG) with the number of cases expected to occur.METHODS: The observed-to-expected (O/E) ratio was detected in the EpSSG countries contributing most of the cases, that is, Italy, France, Spain, the Netherlands, United Kingdom, and Ireland. The observed cases included patients enrolled in any of the EpSSG protocols from October 2008 to October 2015, when all EpSSG protocols were open in these countries. The number of expected cases was calculated from the incidence rates estimated throughout the RARECAREnet database in the countries' population-based cancer registries.RESULTS: In the countries considered, 2,118 cases aged 0-19 years were enrolled in the EpSSG trials from 2008 to 2015: 82.8% were children and 17.2% were adolescents. The O/E ratio was 0.30 among patients 15-19 years old, as opposed to 0.64 for those 0-14 years old. The O/E ratio differed for the different subtypes: in adolescents, it was 0.64 and 0.18 for rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), respectively; in children, it was 0.77 and 0.50, respectively. The O/E ratios differed across the countries considered.CONCLUSIONS: Adolescents were less well represented than children on the EpSSG protocols, with better enrolment for RMS than for NRSTS for all age groups.

KW - Journal Article

U2 - 10.1002/pbc.26348

DO - 10.1002/pbc.26348

M3 - Article

VL - 64

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

M1 - e26348

ER -